Kiora Pharmaceuticals, Inc.
- KPRX
- NASDAQ
- Biotechnology
- Ophthalmology Drugs
- Clinical-Stage Biotech
$2.38
Today −0.83%Quote Oct 19, 2026, 08:00 PM UTC
−13.77%over the last month
Max drawdown −13.8%From 1-month high −13.8%3 months −5.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
13
Market value
$10.5M
Quote Oct 19
Floor
$2.35
1.3% below price
Resistance
$2.44
2.4% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KPRXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free